A team of researchers from Pad Rice Biotech Launch at Rice University has developed an implantable “cytokine plant” that safely causes strong immunoocials against hard cancer for treatment, including metastatic melanoma, pancreatic and colon.
The study, published in The Cancer Immunotherapy MagazineIt details how an immunized protected device near the microenval of the volume containing cells made for local release of interleukin-12 (IL-12)-one “IL-12 Cytokine Factory”-successfully captures the intake of specialized immune cells called (TPEX cells). This TPEX cell intake results in a large, durable population of cells targeted by large molecular profiles, both in isolation and enhanced when implemented in combination with other immunotherapy approaches.
The IL-12 cytokine plants in combination with control points inhibitors successfully eliminated local and remote tumors in preclinical models of metastatic melanoma and pancreatic and pancreatic cancer. In addition to this powerful efficiency signal, the IL-12 cytokine plant showed safety in both mouse models and non-human models.
This published research will serve as a foundation for a new drug application (ind) with the US FDA in early 2026, and RBL LLC is expecting to launch an emerging biotechnology company focusing on IL-12 Kitokokini’s innovative technology.
“We designed the IL-12 cytokine plant to enhance immunotherapy approaches, while minimizing toxicity, a critical need for the treatment of particularly aggressive cancers,” said Omid Veiseh, Professor of Biomedical, Professor of Pad Launch Rice Biotech. “IL-12 is particularly harmful compared to other cytokines, as our research shows that other cytokines mainly consume homogeneous cells of cells and show reduced efficiency over time, while IL-12 produces a more romantic anti-cancer response.
“We are incredibly grateful to ARPA-H to support them in promoting this innovative work and we hope that this technology will significantly affect the lives of cancer patients by enhancing the effectiveness of immunotherapy approaches to the clinic.”
The utilization of the cellular immune system for the targeting of compact tumors is a common but often full approach to combat cancer, as the relative challenge of effective treatment without toxicity remains vague. Our study shows not only the effectiveness of this technology in preclinical models but also its safety profile, which is a critical aspect as we move on clinical trials. This study represents an important step forward in trying to provide more effective treatments for patients who fight for metastatic cancers. ”
Nathan Reticker-Flynn, Assistant Professor of Otaryngology at Stanford University
The research was supported through a research award for Bio Avenge Bio on Rice, the Texas Cancer Research Institute (RR160047), National Institutes The content is the sole responsibility of the authors and does not necessarily represent the official views of the funding institutions.
Source:
Magazine report:
Nash, A., et al. (2025). Kitoquin factories that produce IL-12 cause precursors of exhausted T cells and eliminate primary and metastatic tumors. Newspaper for cancer immunotherapy. Doi.org/10.1136/JitC-2024-010685.
